Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma ; volume:58 ; number:9 ; day:11 ; month:7 ; year:2023 ; pages:908-924 ; date:9.2023
Journal of gastroenterology ; 58, Heft 9 (11.7.2023), 908-924, 9.2023
- Creator
-
Peng, Min
Li, Hui
Cao, Huan
Huang, Yamei
Yu, Weiping
Shen, Chuanlai
Gu, Jinyang
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00535-023-02012-8
- URN
-
urn:nbn:de:101:1-2023110309321406682034
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Peng, Min
- Li, Hui
- Cao, Huan
- Huang, Yamei
- Yu, Weiping
- Shen, Chuanlai
- Gu, Jinyang
- SpringerLink (Online service)
Other Objects (12)
uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis
Regulation of lymphangiogenesis in the diaphragm by macrophages and VEGFR-3 signaling
Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases
Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c‐KIT, and RET Anti‐Targets
Enhancement of cardiac lymphangiogenesis by transplantation of CD34+VEGFR-3+ endothelial progenitor cells and sustained release of VEGF-C
Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Targeting FGFR for cancer therapy
uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis
Regulation of lymphangiogenesis in the diaphragm by macrophages and VEGFR-3 signaling
Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases
Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c‐KIT, and RET Anti‐Targets
Enhancement of cardiac lymphangiogenesis by transplantation of CD34+VEGFR-3+ endothelial progenitor cells and sustained release of VEGF-C
Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Targeting FGFR for cancer therapy
uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis
Regulation of lymphangiogenesis in the diaphragm by macrophages and VEGFR-3 signaling
Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases
Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c‐KIT, and RET Anti‐Targets
Enhancement of cardiac lymphangiogenesis by transplantation of CD34+VEGFR-3+ endothelial progenitor cells and sustained release of VEGF-C
Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage